CLINICAL_TRIALS
trial_result
· 2020-02-28
Clinical Trial Update: Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients [Phase 2]
Summary
Long-term extension study of QCC374 in pulmonary arterial hypertension (Phase 2) was terminated; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: TERMINATED | Results posted: 2020-02-28